SIR2501 for Peripheral Neuropathy

This trial tests a new drug, SIR2501, to determine its effectiveness in preventing chemotherapy-induced peripheral neuropathy (CIPN). CIPN can cause tingling, numbness, or pain in the hands and feet and often affects individuals undergoing chemotherapy for solid tumors. The study will assess the safety and tolerability of SIR2501 by testing three different doses. Adults with solid tumors who are about to start paclitaxel-based chemotherapy may qualify, provided they do not already have peripheral neuropathy or other conditions that could impact the study. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group of participants.

The trial requires that you do not use medications known to reduce chemotherapy-induced peripheral neuropathy, and you cannot have conditions or take medications that interfere with neuropathy assessment.

Research suggests that SIR2501 might be safe for humans. People who have taken similar treatments in the past have generally tolerated these drugs well. Reports show no safety concerns, and earlier studies noted no major side effects. Additionally, SIR2501 targets a protein that helps prevent nerve damage, and lab tests have shown it protects nerves. While this indicates potential safety, further research is needed to confirm these findings.¹²³⁴⁵

Most treatments for peripheral neuropathy focus on managing symptoms through medications like gabapentin or duloxetine, which often work by altering nerve signals. But SIR2501 is different because it targets the underlying nerve damage itself. Researchers are excited about SIR2501 because it uses a novel mechanism that aims to repair and regenerate damaged nerves, potentially addressing the root cause rather than just alleviating symptoms. This could mean more effective, long-term relief for patients suffering from this condition.

Research has shown that SIR2501 might help with chemotherapy-induced peripheral neuropathy (CIPN), a common side effect of chemotherapy with no effective treatments currently available. This makes CIPN a critical unmet medical need. Early findings suggest that SIR2501 could help manage CIPN symptoms. Although limited data exists on its effectiveness in humans, SIR2501 might protect nerve cells from chemotherapy-induced damage. This protection could reduce symptoms like tingling, numbness, or pain in the hands and feet for patients undergoing treatment.⁶⁷⁸⁹¹⁰